Industry
Biotechnology
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 11:50 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 4:38 pm
Portfolio Pulse from Henry Khederian
May 22, 2024 | 4:26 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 3:13 pm
Portfolio Pulse from Benzinga Insights
May 22, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 11:36 am
Portfolio Pulse from Benzinga Newsdesk
April 15, 2024 | 12:35 pm
Portfolio Pulse from Vandana Singh
February 20, 2024 | 9:10 pm
Portfolio Pulse from Benzinga Insights
February 20, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Insights
January 25, 2024 | 9:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.